Closing the HRR testing gap in advanced prostate cancer: Influence of audit-feedback on testing and sustainability.
584 Background: NCCN guidelines recommend germline testing and support biomarker-directed somatic homologous recombination repair (HRR) testing for men with high-risk (HR), very high-risk (VHR), regional, and metastatic prostate cancer, yet uptake remains suboptimal. A community oncology practice leveraged exis...